Immune checkpoint inhibitors (ICIs) have improved outcomes for subsets of patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC), yet objective response rates remain low (∼15-25%), underscoring the need for tools that s... ...

请注册登录后继续浏览